

Special Issue

Novel Progress in Non-alcoholic Fatty Liver Diseases

Message from the Guest Editor

Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum of complications from simple steatosis, steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC). NAFLD is the most prevalent liver disease worldwide. Recently, an increasing number of NAFLD patients have had accompanying co-morbidities, including type 2 diabetes (T2D), obesity, and cardiovascular disease, leading to the designation of a new subtype of liver disease: metabolic-associated fatty liver disease (MAFLD). There is still some ongoing etymological debate regarding the etiology and diagnosis of MAFLD vs. NAFLD. This Special Issue will allow researchers and clinicians to clarify the commonalities and differences among these liver diseases so that we can better understand pathogenesis and therapeutic targets to design new and effective treatment options. Here, we will highlight articles in epidemiology, cellular and molecular mechanisms of liver disease, animal models to study NAFLD and MAFLD, as well as novel therapies, and clinical aspects of liver diseases as we currently understand them.

Guest Editor

Dr. Kristine Griffett

Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA

Deadline for manuscript submissions

closed (30 April 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/149917

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).